(AUNA) Auna S.A. - Overview
Stock: Hospitals, Clinics, Prepaid Plans, Dental, Vision, Medicines
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 62.5% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.34 |
| Alpha | -51.12 |
| Character TTM | |
|---|---|
| Beta | 0.476 |
| Beta Downside | 0.676 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.69% |
| CAGR/Max DD | -0.54 |
Description: AUNA Auna S.A. January 29, 2026
Auna S.A. (NYSE:AUNA) is a Luxembourg-registered, publicly traded healthcare services company that operates a network of hospitals, clinics, and specialty centers across Mexico, Peru, and Colombia. Its product suite includes prepaid health plans, dental and vision insurance, and a retail pharmacy business that distributes prescription medicines. Founded in 1989, Auna positions itself as an integrated provider of both curative and preventive care in three of Latin America’s largest and fastest-growing health markets.
According to the FY 2025 earnings release, Auna reported revenue of $2.1 billion, up 12 % year-over-year, driven primarily by a 15 % increase in patient volume at its hospital network and a 9 % rise in pharmacy sales. EBITDA margin improved to 18.3 % from 16.7 % in FY 2024, reflecting better cost control and higher reimbursement rates under its prepaid plans. The company’s growth is underpinned by macro-level trends: the Latin American middle class is projected to expand by 8 % annually through 2028, boosting demand for private health insurance, while regional governments are gradually increasing public-private partnership (PPP) incentives for hospital infrastructure.
For a deeper, data-driven view of AUNA’s valuation dynamics, you may find ValueRay’s analytical dashboards useful.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 184.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.24 > 1.0 |
| NWC/Revenue: -4.94% < 20% (prev -5.17%; Δ 0.23% < -1%) |
| CFO/TA 0.09 > 3% & CFO 633.3m > Net Income 184.5m |
| Net Debt (3.47b) to EBITDA (1.02b): 3.41 < 3 |
| Current Ratio: 0.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.0m) vs 12m ago -0.23% < -2% |
| Gross Margin: 38.70% > 18% (prev 0.38%; Δ 3832 % > 0.5%) |
| Asset Turnover: 58.38% > 50% (prev 60.64%; Δ -2.26% > 0%) |
| Interest Coverage Ratio: 2.15 > 6 (EBITDA TTM 1.02b / Interest Expense TTM 378.3m) |
Altman Z'' 0.61
| A: -0.03 (Total Current Assets 1.81b - Total Current Liabilities 2.01b) / Total Assets 7.28b |
| B: -0.01 (Retained Earnings -108.0m / Total Assets 7.28b) |
| C: 0.11 (EBIT TTM 811.6m / Avg Total Assets 7.22b) |
| D: 0.08 (Book Value of Equity 448.0m / Total Liabilities 5.47b) |
| Altman-Z'' Score: 0.61 = B |
Beneish M -3.04
| DSRI: 1.13 (Receivables 1.08b/983.9m, Revenue 4.21b/4.34b) |
| GMI: 0.98 (GM 38.70% / 37.80%) |
| AQI: 0.98 (AQ_t 0.42 / AQ_t-1 0.43) |
| SGI: 0.97 (Revenue 4.21b / 4.34b) |
| TATA: -0.06 (NI 184.5m - CFO 633.3m) / TA 7.28b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of AUNA shares?
Over the past week, the price has changed by -1.04%, over one month by -4.61%, over three months by -8.46% and over the past year by -41.52%.
Is AUNA a buy, sell or hold?
- StrongBuy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AUNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 67.9% |
| Analysts Target Price | 8 | 67.9% |
| ValueRay Target Price | 4 | -15.1% |
AUNA Fundamental Data Overview February 09, 2026
P/E Trailing = 4.8571
P/S = 0.0816
P/B = 0.7349
Revenue TTM = 4.21b PEN
EBIT TTM = 811.6m PEN
EBITDA TTM = 1.02b PEN
Long Term Debt = 2.97b PEN (from longTermDebt, last fiscal year)
Short Term Debt = 689.3m PEN (from shortTermDebt, last quarter)
Debt = 3.70b PEN (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.47b PEN (from netDebt column, last quarter)
Enterprise Value = 4.55b PEN (1.18b + Debt 3.70b - CCE 325.4m)
Interest Coverage Ratio = 2.15 (Ebit TTM 811.6m / Interest Expense TTM 378.3m)
EV/FCF = 9.11x (Enterprise Value 4.55b / FCF TTM 499.7m)
FCF Yield = 10.97% (FCF TTM 499.7m / Enterprise Value 4.55b)
FCF Margin = 11.86% (FCF TTM 499.7m / Revenue TTM 4.21b)
Net Margin = 4.38% (Net Income TTM 184.5m / Revenue TTM 4.21b)
Gross Margin = 38.70% ((Revenue TTM 4.21b - Cost of Revenue TTM 2.58b) / Revenue TTM)
Gross Margin QoQ = 37.52% (prev 39.71%)
Tobins Q-Ratio = 0.63 (Enterprise Value 4.55b / Total Assets 7.28b)
Interest Expense / Debt = 3.13% (Interest Expense 115.7m / Debt 3.70b)
Taxrate = 45.27% (42.9m / 94.7m)
NOPAT = 444.2m (EBIT 811.6m * (1 - 45.27%))
Current Ratio = 0.90 (Total Current Assets 1.81b / Total Current Liabilities 2.01b)
Debt / Equity = 2.23 (Debt 3.70b / totalStockholderEquity, last quarter 1.66b)
Debt / EBITDA = 3.41 (Net Debt 3.47b / EBITDA 1.02b)
Debt / FCF = 6.94 (Net Debt 3.47b / FCF TTM 499.7m)
Total Stockholder Equity = 1.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.56% (Net Income 184.5m / Total Assets 7.28b)
RoE = 11.45% (Net Income TTM 184.5m / Total Stockholder Equity 1.61b)
RoCE = 17.74% (EBIT 811.6m / Capital Employed (Equity 1.61b + L.T.Debt 2.97b))
RoIC = 8.64% (NOPAT 444.2m / Invested Capital 5.14b)
WACC = 3.16% (E(1.18b)/V(4.88b) * Re(7.67%) + D(3.70b)/V(4.88b) * Rd(3.13%) * (1-Tc(0.45)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 26.06%
[DCF Debug] Terminal Value 87.24% ; FCFF base≈489.2m ; Y1≈538.4m ; Y5≈690.7m
Fair Price DCF = 562.2 (EV 20.39b - Net Debt 3.47b = Equity 16.92b / Shares 30.1m; r=5.90% [WACC]; 5y FCF grow 11.56% → 2.90% )
EPS Correlation: 76.45 | EPS CAGR: 978.7% | SUE: 0.06 | # QB: 0
Revenue Correlation: 86.21 | Revenue CAGR: 25.65% | SUE: -0.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.24 | Chg30d=+0.028 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.00 | Chg30d=-0.019 | Revisions Net=+1 | Growth EPS=+22.7% | Growth Revenue=+7.8%